S
Sharmilan Thanendrarajan
High Impact
Associate Professor
faculty
Internal Med, College of Medicine
32 h-index
256 pubs
3,608 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
Sharmilan Thanendrarajan, M.D., is an Associate Professor in the Department of Internal Medicine at the University of Arkansas for Medical Sciences, where he is affiliated with the Myeloma Institute for Research and Therapy. His clinical focus and research interests are centered on multiple myeloma.
Dr. Thanendrarajan's research investigates the molecular evolution of multiple myeloma, including the pathways from smoldering myeloma to active disease and relapse. He also studies the role of the immune microenvironment in disease progression using single-cell analysis. His work examines the impact of emerging therapies, such as bispecific antibodies and chimeric antigen receptor (CAR)-T cell therapy, on multiple myeloma treatment and outcomes. This includes analyzing the risks of infection associated with these therapies and characterizing their efficacy in real-world settings.
His scholarship includes 255 publications, with an h-index of 31 and over 3,400 citations. Dr. Thanendrarajan has collaborated with researchers at the University of Arkansas for Medical Sciences, including Maurizio Zangari, Carolina Schinke, Samer Al Hadidi, and Frits van Rhee, on numerous publications. He is a member of several professional societies, including the European Society for Medical Oncology and the European Myeloma Network.
Research Overview
Sharmilan Thanendrarajan, M.D., is an Assistant Professor of Medicine with the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences.Dr. Thanendrarajan trained as a fellow in Hematology/Oncology at University Clinic of Bonn in Germany. He trained as a resident in Internal Medicine at University Clinic of Bonn and General Hospital of Hagen. Dr. Thanendrarajan earned his M.D. from the Medical College of Ruhr-University in Bochum, Germany. He is a member of the German Society of Internal Medicine, the German Cancer Society, the German Society for Hematology and Oncology, the European Society for Medical Oncology and the European Myeloma Network. Dr. Thanendrarajan is board certified in Germany in Internal Medicine and Hematology/Oncology. Publications: http://www.ncbi.nlm.nih.gov/pubmed/?term=thanendrarajan+sTo make an appointment with Dr. Thanendrarajan, please call 1-888-MYELOMA.
Metrics
- h-index: 32
- Publications: 256
- Citations: 3,608
Selected Publications
-
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma (2025)
-
Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma (2025)
-
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)
-
Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study (2024)
-
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)
-
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma (2024)
-
Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab (2024)
-
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation (2024)
-
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study (2024)
-
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma (2024)
-
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems (2024)
-
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024)
-
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up (2023)
-
Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma (2023)
-
Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study (2023)
Grants & Funding
- No FP attached GlaxoSmithKline Principal Investigator
Collaboration Network
Top Collaborators
Maurizio Zangari
University of Arkansas for Medical Sciences
48 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
Showing 5 of 48 shared publications
Frits van Rhee
University of Arkansas for Medical Sciences
48 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
Showing 5 of 48 shared publications
Carolina Schinke
University of Arkansas for Medical Sciences
48 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
Showing 5 of 48 shared publications
Samer Al Hadidi
University of Arkansas for Medical Sciences
35 shared publications
In database
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms
Showing 5 of 35 shared publications
Meera Mohan
17 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
- Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma
Showing 5 of 17 shared publications
John D. Shaughnessy
University of Arkansas for Medical Sciences
17 shared publications
In database
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis
- A gene signature can predict risk of MGUS progressing to multiple myeloma
Showing 5 of 17 shared publications
Cody Ashby
University of Arkansas for Medical Sciences
14 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
Showing 5 of 14 shared publications
Daisy Alapat
University of Arkansas for Medical Sciences (US)
14 shared publications
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
Showing 5 of 14 shared publications
Fenghuang Zhan
University of Arkansas for Medical Sciences
13 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis
Showing 5 of 13 shared publications
Anikó Szabó
Medical College of Wisconsin (US)
13 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
- Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma
Showing 5 of 13 shared publications
Guido Tricot
University of Arkansas for Medical Sciences
13 shared publications
In database
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
Showing 5 of 13 shared publications
Bart Barlogie
University of Arkansas for Medical Sciences
11 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
- A gene signature can predict risk of MGUS progressing to multiple myeloma
Showing 5 of 11 shared publications
Clyde Bailey
University of Arkansas for Medical Sciences
11 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
Showing 5 of 11 shared publications
Binod Dhakal
Medical College of Wisconsin (US)
9 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
- Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
Showing 5 of 9 shared publications
Anita D’Souza
Medical College of Wisconsin (US)
9 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
- Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
Showing 5 of 9 shared publications
Similar Researchers
Based on overlapping research topics
Carolina Schinke
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Samer Al Hadidi
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Immune Response and Inflammation
Cancer Treatment and Pharmacology
David E. Mery
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Guido Tricot
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Henry K. Wong
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Maurizio Zangari
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Immune Response and Inflammation